Want to join the conversation?
$BAX 2Q15 Call: Performance in the quarter was driven by mid to high single digit growth in our peritoneal dialysis business and double digit growth in the acute business. This growth was offset by lower sales in our chronic hemodialysis business, resulting from our previously mentioned decision to forgo certain lower margin sales opportunities.
Unicorn Frappuccino. The latest hit from $SBUX. Can't wait to see how this will affect its results.
At what point should $AMZN consider a stock split? $1000 per share seems pretty high.